Literature DB >> 21298649

Association of warfarin use with valvular and vascular calcification: a review.

Chandrasekar Palaniswamy1, Arunabh Sekhri, Wilbert S Aronow, Ankur Kalra, Stephen J Peterson.   

Abstract

Vitamin K is required for the activity of various biologically active proteins in our body. Apart from clotting factors, vitamin K-dependent proteins include regulatory proteins like protein C, protein S, protein Z, osteocalcin, growth arrest-specific gene 6 protein, and matrix Gla protein. Glutamic acid residues in matrix Gla protein are γ-carboxylated by vitamin K-dependent γ-carboxylase, which enables it to inhibit calcification. Warfarin, being a vitamin K antagonist, inhibits this process, and has been associated with calcification in various animal and human studies. Though no specific guidelines are currently available to prevent or treat this less-recognized side effect, discontinuing warfarin and using an alternative anticoagulant seems to be a reasonable option. Newer anticoagulants such as dabigatran and rivaroxaban offer promise as future therapeutic options in such cases. Drugs including statins, alendronate, osteoprotegerin, and vitamin K are currently under study as therapies to prevent or treat warfarin-associated calcification.
Copyright © 2011 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose. © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298649      PMCID: PMC6652734          DOI: 10.1002/clc.20865

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  18 in total

1.  Aortic valve reconstruction with autologous pericardium for dialysis patients.

Authors:  Isamu Kawase; Shigeyuki Ozaki; Hiromasa Yamashita; Shin Uchida; Yukinari Nozawa; Takayoshi Matsuyama; Mikio Takatoh; So Hagiwara
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-20

Review 2.  Mineralization/anti-mineralization networks in the skin and vascular connective tissues.

Authors:  Qiaoli Li; Jouni Uitto
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

3.  Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification.

Authors:  Kelly E Beazley; Stephanie Deasey; Florence Lima; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

4.  Matrix Gla protein deficiency causes arteriovenous malformations in mice.

Authors:  Yucheng Yao; Medet Jumabay; Anthony Wang; Kristina I Boström
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

Review 5.  Vitamin K status in chronic kidney disease: a report of a study and a mini-review.

Authors:  Kieran Voong; Dominic Harrington; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

6.  Two cases of warfarin-induced tracheobronchial calcification after Fontan surgery.

Authors:  Luke Eckersley; John Stirling; Christopher Occleshaw; Nigel Wilson
Journal:  Pediatr Cardiol       Date:  2014-03-02       Impact factor: 1.655

Review 7.  Genetic pathways of vascular calcification.

Authors:  Marion A Hofmann Bowman; Elizabeth M McNally
Journal:  Trends Cardiovasc Med       Date:  2012-05       Impact factor: 6.677

8.  Reducing Jagged 1 and 2 levels prevents cerebral arteriovenous malformations in matrix Gla protein deficiency.

Authors:  Yucheng Yao; Jiayi Yao; Melina Radparvar; Ana M Blazquez-Medela; Pierre J Guihard; Medet Jumabay; Kristina I Boström
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 9.  Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?

Authors:  Thanh-Mai Vo; Sinee Disthabanchong
Journal:  World J Cardiol       Date:  2014-05-26

10.  Transglutaminase inhibitors attenuate vascular calcification in a preclinical model.

Authors:  Kelly E Beazley; Derek Banyard; Florence Lima; Stephanie C Deasey; Dmitry I Nurminsky; Mikhail Konoplyannikov; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-01       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.